Organization (Other)
Joslin Diabetes Center
ClinicalTrials.gov lists Joslin Diabetes Center as lead sponsor of 80 trials. It has 11 active development programs and 17 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 2 registered with a 2026 start date. The dashed outline is the pace from the 2 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 3.4 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Joslin Diabetes Center: 80 lead-sponsored trials and 1 legal-entity registration.
Disease areas (39)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Diabetes Mellitus | 75 |
| Diabetes Mellitus, Type 1 | 28 |
| Diabetes Mellitus, Type 2 | 26 |
| Obesity | 21 |
| Hypoglycemia | 16 |
Showing 5 of 39 disease areas.
Trials by start year as sponsor or collaborator (28)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 4 |
| 2024 | 2 |
| 2023 | 4 |
| 2022 | 5 |
| 2021 | 5 |
| 2020 | 4 |
| 2019 | 6 |
| 2018 | 4 |
| 2017 | 8 |
Showing 10 of 28 years.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (11)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| SITAGLIPTIN | Diabetes Mellitus, Type 1 | Phase 2/3 | 1 |
| Metformin Extended Release (ER) Oral Tablet | Diabetes Mellitus | Phase 2/3 | 1 |
| Metformin Extended Release (ER) Oral Tablet | Diabetes Mellitus, Type 1 | Phase 2/3 | 1 |
| SITAGLIPTIN | Diabetes Mellitus | Phase 2/3 | 1 |
| Exercise | Obesity | Not reported | 1 |
Showing 5 of 11 active programs.
Approved assets (17)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Glucagon for Injection (Bedford Laboratories) | 2 |
| [1-13C] glucose | 1 |
| [13C9, 15N1]-glucagon | 1 |
| [2-13C] glucose | 1 |
| Glargine Insulin | 1 |
Showing 5 of 17 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 56% hit target (n=27) | 28% on time (n=25) |
Journals published in (91)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Diabetes care | 33 |
| Diabetic medicine : a journal of the British Diabetic Association | 9 |
| Diabetes technology & therapeutics | 8 |
| The New England journal of medicine | 8 |
| Clinical journal of the American Society of Nephrology : CJASN | 7 |
Showing 5 of 91 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 73 | 7 | 2024-12-10 |
Financing and grant events (211)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2025-09-22 | NIH grant | 85,500 | Reporter |
| 2025-09-12 | NIH grant | 150,583 | Reporter |
| 2025-09-12 | NIH grant | 828,792 | Reporter |
| 2025-09-10 | NIH grant | 543,652 | Reporter |
| 2025-09-08 | NIH grant | 645,002 | Reporter |
Showing 5 of 211 events.
Manufacturing and distribution sites (1)
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| JOSLIN DIABETES CENTER | BOSTON, US | FDA |
Organization relationships (41)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Beth Israel Deaconess Medical Center | Co sponsors trial with | 2 |
| Jaeb Center for Health Research | Co sponsors trial with | 2 |
| University of Colorado System | Co sponsors trial with | 2 |
| Yale University | Co sponsors trial with | 2 |
| Mount Sinai Health System | Co sponsors trial with | 2 |
Showing 5 of 41 relationships.
Latest dated events (388)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-01-27 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-01-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-12-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-09-22 | NIH grant | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-09-15 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 388 events.
CLIA clinical laboratory certificates (4)
Shown in this order: active first, then certificate type.
| Lab | Certificate | Status |
|---|---|---|
| JOSLIN DIABETES CENTER INC | Certificate of compliance | Terminated |
| JOSLIN DIABETES CENTER | Certificate of waiver | Terminated |
| JOSLIN DIABETES CENTER | Certificate of waiver | Terminated |
| JOSLIN DIABETES CENTER | Certificate of waiver | Terminated |
Biomarker capability evidence (112)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ALB | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
| CST3 | Trial collaborator | Named in trial inclusion criteria |
| CST3 | Trial collaborator | Primary endpoint in a Phase 3 trial |
Showing 5 of 112 evidence rows.
Biomarkers this organization publishes on (463)
Shown in this order: most publications first.
Showing 5 of 463 biomarkers.
On Scientist.com
Joslin Diabetes Center is listed as a research supplier in the Scientist.com network.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, climate targets, as filed, and workforce and board diversity, as filed.
Work with Joslin Diabetes Center, Inc. on Scientist.com
For prices, more details, or to contact Joslin Diabetes Center, Inc., visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.